Deerfield Management Company, L.P.'s Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Oct 28, 2021
- Accession no.
- 0001193805-21-001508
- Filed
- Oct 28, 2021, 7:15 PM ET
- Trade date
- Oct 26, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market purchases total $12.4M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deerfield Management Company, L.P.CIK 0001009258 | 10% Owner, Other: Possible Member of 10% Group |
| Deerfield Mgmt L.P.CIK 0001010823 | 10% Owner, Other: Possible Member of 10% Group |
| Deerfield Partners, L.P.CIK 0001301041 | 10% Owner, Other: Possible Member of 10% Group |
| Flynn James ECIK 0001352546 | 10% Owner, Other: Possible Member of 10% Group |
| Deerfield Mgmt V, L.P.CIK 0001876688 | 10% Owner, Other: Possible Member of 10% Group |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionAcquired | +756,472 | –F1 | – | 756,472 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +756,472 | –F1 | – | 756,472 | Indirect | |
| Oct 26, 2021 | Common Stock | PPurchaseAcquired | +387,500 | $16.00 | +$6,200,000 | 1,143,972 | Indirect | |
| Oct 26, 2021 | Common Stock | PPurchaseAcquired | +387,500 | $16.00 | +$6,200,000 | 1,143,972 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series C Preferred Stock automatically converted into 0.1053 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-9.5 reverse split of the Issuer's common stock effected by the Issuer on October 15, 2021).
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
Remarks
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn